Eradication of Helicobacter pylori infection with a new bismuth-based quadruple therapy in clinical practice.

摘要: Abstract Introduction The eradication of Helicobacter pylori infection represents a clinical challenge. Objective To evaluate the efficacy and safety quadruple therapy with esomeprazole plus 3-in-1 capsule containing bismuth subcitrate, metronidazole tetracycline, probiotics in patients diagnosed H. routine practice. Methods A prospective, interventional, single-centre open-label study consecutive confirmed indication for infection. Patients were treated three capsules Pylera® four times day (breakfast, lunch, afternoon snack dinner), 40 mg twice daily 10 days (30 min before breakfast dinner) 30 days. Eradication was by labelled urea breath test performed at least 28 after end treatment. Results total 100 consecutively enrolled. Twenty-five (25.0%) had prior history treatment their In intention-to-treat population, rates 90.7% (68/75) 80.0% (20/25) as first line or rescue therapy, respectively. Eighteen (18%) one adverse event, most which (89%) mild. Conclusion Ten regimen bismuth, tetracycline is an effective safe strategy